Quince Therapeutics Reports $16M Net Loss, Decreases Operating Expenses by 63%

Quince Therapeutics, Inc. reported a net loss of $16.0 million for the three months ended June 30, 2025, a significant decrease from the $27.7 million loss recorded in the same period of the previous year. The company’s total operating expenses for the quarter were $10.4 million, down 63% from $28.2 million in the prior year, primarily due to the absence of a goodwill impairment charge that had impacted the previous year’s results. Research and development expenses increased by 58% to $6.6 million, driven by ongoing costs associated with the Phase 3 NEAT clinical trial for its lead product, eDSP, which is aimed at treating Ataxia-Telangiectasia (A-T).

In the first half of 2025, Quince's net loss was $31.1 million, compared to a loss of $38.9 million in the same period of 2024. The company’s total operating expenses for the six months ended June 30, 2025, were $25.3 million, a decrease of 36% from $39.4 million in the prior year. The reduction in expenses was attributed to the lack of goodwill impairment charges and a decrease in fair value adjustments for contingent consideration. However, research and development expenses surged by 87% to $14.7 million, reflecting the ramp-up of clinical trial activities.

Quince Therapeutics has made strategic advancements, including the completion of enrollment in its Phase 3 NEAT clinical trial, which now includes 105 participants. The company anticipates reporting topline results in the first quarter of 2026. Additionally, on August 7, 2025, Quince entered into a strategic partnership with Option Care Health, Inc. to facilitate the commercial development of eDSP, leveraging Option Care's extensive network for effective treatment delivery.

As of June 30, 2025, Quince had cash, cash equivalents, and short-term investments totaling $34.7 million, which the company believes will fund operations into the second quarter of 2026. However, management has expressed concerns regarding the sufficiency of these funds to support ongoing operations and has indicated the need for additional financing. The company plans to explore various funding avenues, including public offerings and strategic partnerships, to ensure continued development of its product candidates.